Topics
Glioblastoma | Treatment | Clinical trials | Ipilimumab
Home > Publications > Topics > Glioblastoma > Treatment > Clinical trials > Ipilimumab
2024
Sloan
AE, Winter K, Gilbert MR, Aldape K, Choi S, Wen PY, Butowski N,
Iwamoto FM, Raval RR, Voloschin AD, Kamiya-Matsuoka C, Won M,
Mehta MP.
NRG-BN002:
Phase I Study of Ipilimumab, Nivolumab, and the Combination in
Patients with Newly Diagnosed GBM.
Neuro
Oncol.
2024 Jun 14:noae058. doi:
10.1093/neuonc/noae058. PMID:
38874333. Interventional study˰ ˍ
2025
Brown NF, McBain C, Brazil L,
Peoples S, Jefferies S, Harris F, Vinayan A, Plaha P, Brooks C,
Hussain S, Dutton SJ, Cook J, Ng SM, Levy S, Coutts T, Mulholland
P.
Ipilimumab
with temozolomide vs. temozolomide alone after surgery and
chemoradiotherapy in recently diagnosed glioblastoma: a randomized
phase II clinical trial.
Neurooncol
Adv. 2025 May
26;7(1):vdaf032. doi:
10.1093/noajnl/vdaf032. PMID:
40800123. Interventional study. ˍ
ISRCTN.com
ID: ISRCTN84434175.
Lassman AB, Polley MC, Iwamoto FM, Sloan AE, Wang TJC, Aldape KD,
Wefel JS, Gondi V, Gutierrez AN, Manasawala MH, Gilbert MR, Sulman
EP, Wolchok JD, Green RM, Neil EC, Lukas RV, Goldlust SA, Snuderl
M, Galbraith K, Dignam JJ, Won M, Mehta MP.
Dual
Immune Check Point Blockade in MGMT-Unmethylated
Newly Diagnosed Glioblastoma: NRG Oncology BN007, a Randomized
Phase II/III Clinical Trial.
J
Clin Oncol. 2025 Aug 8:JCO2500618. doi:
10.1200/JCO-25-00618. PMID:
40779733. Interventional study. ˍ
NRGoncology.org
ID: NRG-BN007.
Neuro-Oncology Clinical Research Program; Camphausen K.
Phase
II Trial Evaluating the Association of Peripheral Blood
Immunologic Response to Therapeutic Response After Adjuvant
Treatment with Immune Checkpoint Inhibition (ICI) in Patients with
Newly Diagnosed Glioblastoma or Gliosarcoma.
medRxiv
[Preprint]. 2025 Dec 30:2025.12.23.25342908. doi:
10.64898/2025.12.23.25342908. PMID:
41607658. Trial
registration ID: NCT04817254. ˍ
2026
Sun L, Markus LF, Sanchez JC, Lai TJ, Lee EQ, Li G, Kim J, Zhuang
Z, Acevedo B, Everson RG, Mellinghoff IK, Aquilanti E, Nicolas
Gonzalez Castro L, Ricardo McFaline-Figueroa J, Nayak L, Beroukhim
R, Chong RA, Stone J, Kaley T, Schaff L, Wilcox J, Westergaard C,
Russ A, Lavallee M, Chukwueke U, Van den Abbeele AD, Lim M,
Ellingson BM, Reardon DA, Cloughesy TF, Prins RM, Wen PY.
Neoadjuvant PD1 plus CTLA-4 immune
checkpoint blockade in surgically resectable recurrent
glioblastoma: a randomized surgical window-of-opportunity trial.
Nat
Commun. 2026 Sep 5;17(1):10560. doi:
10.1038/s41467-026-77433-z. PMID:
42838943. Trial
registration ID: NCT04606316. ˍ